Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposomal ropivacaine (LY03009) is a long-acting local anesthetic formulation developed by Luye Pharma. It utilizes a multivesicular liposome delivery system to encapsulate ropivacaine, an amide-type local anesthetic, allowing for the sustained release of the drug at the site of administration. This formulation is designed to provide prolonged analgesia, potentially lasting up to 72 hours, which is significantly longer than the duration provided by standard ropivacaine hydrochloride injections. By inhibiting voltage-gated sodium channels on nerve fibers, it prevents the initiation and conduction of nerve impulses, thereby providing effective postoperative pain relief. It is primarily being investigated for the management of postoperative pain following various surgical procedures, including hemorrhoidectomy and bunionectomy, with the goal of reducing the reliance on systemic opioids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liposomal ropivacaine.